Biostatistics, Data Science, Astellas Pharma Global Development, Inc., Northbrook, Illinosis, USA.
Real World Evidence, Oncology Medical, Bristol-Myers Squibb, Tokyo, Japan.
Pharm Stat. 2022 Nov;21(6):1309-1323. doi: 10.1002/pst.2246. Epub 2022 Jun 16.
Dose-finding trials play a key role in the entire drug development process to determine optimal doses for regulatory approval. We address confirmatory efficacy testing for individual dose-placebo comparisons in the context of a dose-finding trial designed with multiple comparison procedures-modeling (MCP-Mod). An extension of the MCP-Mod, called closed MCP-Mod, has been proposed to carry out the MCP-Mod in conjunction with pairwise dose-placebo comparisons; however, an issue associated with the misspecification of candidate dose-response models remains. We consider another way to combine the MCP-Mod and the individual dose-placebo comparisons using serial gatekeeping procedures with fixed sequence, Holm, Hochberg, and step-down Dunnett procedure. The method controls the family-wise error rate in the strong sense and is simple enough to be implemented by existing software. Simulation studies suggested that the serial gatekeeping procedure was comparable with the closed MCP-Mod in terms of statistical power to detect the efficacy of at least one dose, and both methods were capable of pursuing the efficacy claim rather than just establishing the dose-response signal with less than a 20% increase in sample size when assuming monotonic dose-response shapes. The serial gatekeeping procedure would have advantages in the simplicity of implementation and ease of interpretation. The dose-finding trials aiming to declare the dose-response signal, as well as the efficacy of individual doses, would be worth considering as an option to accelerate the drug development program in certain situations.
剂量探索试验在整个药物开发过程中起着关键作用,旨在确定获得监管批准的最佳剂量。我们在设计了多重比较程序-建模(MCP-Mod)的剂量探索试验背景下,解决了针对个体剂量-安慰剂比较的确认疗效检验问题。MCP-Mod 的一种扩展,称为封闭 MCP-Mod,已被提议与成对的剂量-安慰剂比较一起进行 MCP-Mod;然而,候选剂量反应模型的指定不当仍然存在问题。我们考虑了另一种方法,使用具有固定顺序的串行门控程序结合 MCP-Mod 和个体剂量-安慰剂比较。该方法在强意义上控制了总体错误率,并且足够简单,可以通过现有的软件来实现。模拟研究表明,在检测至少一种剂量疗效的统计功效方面,串行门控程序与封闭 MCP-Mod 相当,并且这两种方法都能够在假设单调剂量反应形状的情况下,通过将样本量增加不到 20%,而不是仅仅建立剂量反应信号,来追求疗效主张。串行门控程序在实施的简单性和解释的容易性方面具有优势。旨在宣布剂量反应信号以及个体剂量疗效的剂量探索试验将被视为在某些情况下加速药物开发计划的一种选择,值得考虑。